The $100 billion club gets a shakeup, driven by biotech’s new blue-chip names

2024-02-20
The drug industry officially has two new heavyweights. For the first time, Regeneron and Vertex have crossed the $100 billion market cap threshold. They join about 15 other drugmakers that count as the industry’s biggest, and include other giants like Johnson & Johnson, Merck, and Novartis. And while it’s an arbitrary line, it’s also a signal of how the industry is evolving — both companies are biotechs that have spent years building their R&D identities with a sharper scientific focus and far less dealmaking than typically seen in pharma boardrooms. It’s a sign that new approaches to M&A, R&D and leadership strategies are shaping the future of pharma, and how the newest giants have been built differently.
更多内容,请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
适应症
-
靶点
-
药物
-
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。